Transdisciplinary Innovation Network Against Prostate Cancer

Cancer behaves as a reversible systems disorder of differentiation control.

The RCA framework suggests that cancer cells are not primarily mutant cells β€” they are progenitor cells arrested in an undifferentiated state. This distinction is falsifiable, clinically supported, and opens a fundamentally different research direction.

I
The Key Test

Cancer cells share the phenotype of progenitor cells: proliferation, Warburg metabolism, immature structure. The difference is state, not mutation.

II
Clinical Evidence Β· APL

In Acute Promyelocytic Leukaemia, ATRA restores differentiation and achieves cure β€” demonstrating that internal differentiation control can be re-established.

III
Experimental Evidence Β· Bissell

Mina Bissell's ECM research shows cancer cells can normalise in a healthy tissue environment β€” external differentiation control can also be restored.

The RCA Framework

Repair and Capacity Adaptation (RCA) is a systems-level description of how tissue architecture governs cell fate. Cancer, in this view, is not a cell-autonomous disease β€” it is a failure of the regulatory architecture that controls differentiation.

Stem Cell / Progenitor
Differentiation Signal
(ECM Β· APL)
Mature, Functional Cell
vs. disrupted pathway
Stem Cell / Progenitor
ECM Degraded / Signal Lost
Arrested Progenitor
(= cancer?)

RCA proposes two complementary regulatory layers: internal (differentiation signalling, as in APL/ATRA) and external (tissue microenvironment, as in Bissell's ECM experiments). Cancer may represent failure of both.

"Cancer behaves as a reversible systems disorder of differentiation control β€” consistent with a progenitor cell trapped in an undifferentiated state."

πŸ“„ Read Part I (bioRxiv) πŸ“„ Read Part II (Zenodo)

Three Lines of Evidence

The RCA hypothesis is not proposed in isolation. It is consistent with, and provides a unifying framework for, three independent lines of existing evidence.

Core Hypothesis

Cancer Cell = Trapped Progenitor?

Progenitor cells naturally proliferate, display high metabolic activity (Warburg-like), and have an immature cellular structure. These are the same properties that define cancer cells. RCA suggests the difference is state, not irreversible mutation.

If true: cancer is not a gain-of-function disease but a loss-of-regulation disease β€” and potentially reversible.
Clinical Evidence

APL: Internal Control Restored

Acute Promyelocytic Leukaemia (APL) involves a differentiation arrest at the promyelocyte stage. All-Trans Retinoic Acid (ATRA) restores the differentiation programme, allowing cells to mature and achieving near-complete cure rates without targeting mutations directly.

RCA framing: internal differentiation control was re-established β€” consistent with the progenitor-arrest model.
Experimental Evidence

Bissell: External Control Restored

Mina Bissell's laboratory demonstrated that cancer cells can normalise their behaviour when placed in a healthy extracellular matrix (ECM). Conversely, normal cells may acquire malignant properties in a disrupted ECM β€” without genetic changes.

RCA framing: external differentiation control was re-established β€” the tissue context determines cell phenotype more than the genome.
Synthesis

RCA Dual Regulatory Architecture

APL and Bissell are not isolated findings β€” they are independent demonstrations of the same principle from different angles. Cancer can be reversed by restoring either internal control (APL/ATRA) or external control (ECM restoration). RCA provides the unifying systems framework above both TME and TOFT.

Proposition: Cancer provides evidence for a dual regulatory architecture governing cell differentiation. RCA suggests this architecture is the missing systems layer above existing frameworks.

A Falsifiable Core

The RCA hypothesis makes a clear, testable prediction. If cancer cells are trapped progenitor cells, they should share a specific phenotypic profile β€” independent of mutation status.

Are cancer cells functionally equivalent to progenitor cells arrested in an undifferentiated state?

Shared Phenotype (Progenitor ↔ Cancer)
  • βœ“ Active proliferation
  • βœ“ Warburg metabolism
  • βœ“ Immature cell structure
  • βœ“ ECM sensitivity
  • βœ“ Differentiation responsiveness (APL)
  • βœ“ Context-dependent behaviour
Conclusion: If the phenotypic overlap is explained by shared ontogeny rather than parallel mutation convergence, this suggests the difference between a progenitor cell and a cancer cell is primarily one of regulatory state, not genetic identity.

We are looking for laboratories willing to co-design the decisive validation experiment.

Join the Experiment

Proposed Experiments

The following experiments are designed to make RCA experimentally tractable. Each test addresses a specific prediction of the progenitor-arrest model.

Research Map β€” Thematic Areas

Prostate

Primary disease focus β€” prostate cancer as model system for ECM-governed differentiation arrest.

Biochemistry

Metabolic signatures of arrested progenitors β€” Warburg effect as phenotypic marker, not driver.

Brain / Nervous System

Neural progenitor arrest in gliomas β€” highest unmet need meets most tractable RCA model.

Epigenetics

Epigenetic locks maintaining progenitor state β€” how differentiation arrest is encoded and reversed.

Cell Communication

Intercellular signalling and gap junction disruption in ECM degradation cascade.

Emergent Systems

Complex systems modelling of tissue-level regulatory collapse β€” beyond the single-cell view.

PBI β€” Psychobiological Interface

The brain's control keyboard β€” the Psychobiological Interface (PBI) β€” represents a set of regulatory channels through which psychological and neuroendocrine states may influence tissue-level differentiation control in the RCA framework.

⚑

Neuroelectric

Bioelectric signalling through tissue β€” potential regulator of ECM integrity and cell polarity.

πŸ§ͺ

Neurochemical

Neurotransmitters as systemic tissue modulators β€” serotonin, dopamine in ECM remodelling.

πŸ”¬

Hormonal

Stress hormones, cortisol, and sex hormones in modulating tissue microenvironment and differentiation.

πŸ«€

Autonomic

Sympathetic/parasympathetic influence on tumour microenvironment β€” emerging clinical evidence.

🧬

Epigenetic

Experience-dependent epigenetic modifications that may encode or unlock progenitor arrest states.

Proposed pathway
Psyche β†’ PBI channels β†’ RCA regulatory architecture β†’ Tissue ECM β†’ Progenitor state
Note: PBI is a hypothesis-generating framework. TINAP does not claim psychosocial factors cause cancer β€” we propose they may influence the tissue regulatory environment in ways consistent with the RCA model. This is a research direction, not a conclusion.

A Systematic Research Program

The RCA hypothesis generates a structured experimental program. Below are the thematic pillars, each with defined questions and testable predictions.

Differentiation Arrest

Core phenotypic characterisation β€” which cancer types show strongest progenitor signatures? Which regulatory checkpoints are disrupted?

ECM Regulation

What ECM components govern differentiation signalling? How does degradation create permissive conditions for progenitor arrest?

Translational Models

Organoid and in vivo models for testing differentiation restoration. APL as the proof-of-concept. What are the counterparts in solid tumours?

Pathogen Pathway

Infection β†’ chronic inflammation β†’ ECM degradation β†’ progenitor arrest. Which pathogens? Which cancer types? What is the mechanistic chain?

Systems Integration

Mathematical modelling of the dual regulatory architecture. When does the system lose stability? What restores it?

Clinical Translation

From experimental validation to regenerative oncology interventions. Differentiation therapy and ECM restoration as complementary approaches.

Published framework:

Let's Validate This

The RCA hypothesis is specific, falsifiable, and experimentally tractable. We are actively seeking partners to design and execute the decisive validation.

  • 🧬
    Laboratories & ECM researchers β€” co-design the progenitor-arrest validation experiment.
  • πŸ₯
    APL / differentiation therapy clinicians β€” extend the differentiation therapy model to solid tumours.
  • πŸ”—
    Systems biology & transdisciplinary centres β€” connect existing evidence and amplify the conversation.
  • πŸ’°
    Foundations & funding bodies β€” support the first experimental validation phase.
Contact Us Support the Research